{"slideshow_credits": null, "snippet": "Buying Allergan would give the drug giant a low-tax domicile in Ireland and one good drug, Botox. But Allergan would accrue nearly all of the upside.", "abstract": null, "section_name": "Business Day", "print_page": null, "document_type": "article", "byline": {"person": [{"firstname": "Robert", "role": "reported", "lastname": "CYRAN", "rank": 1, "organization": ""}], "original": "By ROBERT CYRAN"}, "web_url": "http://www.nytimes.com/2015/11/20/business/dealbook/high-risk-and-low-benefit-in-pfizers-pursuit-of-allergan.html", "lead_paragraph": "Buying Allergan would give the drug giant a low-tax domicile in Ireland and one good drug, Botox. But Allergan would accrue nearly all of the upside.", "headline": {"main": "High Risk and Low Benefit in Pfizer\u2019s Pursuit of Allergan", "content_kicker": "Breakingviews", "kicker": "Breakingviews"}, "_id": "564e1f2338f0d84d3be11021", "word_count": "389", "multimedia": [], "pub_date": "2015-11-20T00:00:00Z", "source": "The New York Times", "news_desk": "Business", "keywords": [{"name": "subject", "value": "Mergers, Acquisitions and Divestitures", "is_major": "N", "rank": "1"}, {"name": "organizations", "value": "Allergan Inc", "is_major": "N", "rank": "2"}, {"name": "organizations", "value": "Pfizer Inc", "is_major": "N", "rank": "3"}, {"name": "subject", "value": "Federal Taxes (US)", "is_major": "N", "rank": "4"}, {"name": "subject", "value": "Drugs (Pharmaceuticals)", "is_major": "N", "rank": "5"}, {"name": "persons", "value": "Read, Ian C", "is_major": "N", "rank": "6"}], "blog": [], "subsection_name": "DealBook", "type_of_material": "News"}